RPTX•benzinga•
Repare Therapeutics Q4 2024 GAAP EPS $(0.67) Beats $(0.79) Estimate, $152.8M In Cash And Cash Equivalents And Marketable Securities Provides Runway To Late-2027
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 3, 2025 by benzinga